Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …

Recent research into the pathophysiology and treatment of atopic dermatitis (AD) has shown
notable progress. An increasing number of aspects of the immune system are being …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

Toll-like receptor–driven and interleukin-1 (IL-1) receptor–driven inflammation mediated by
IL-1 receptor–associated kinase 4 (IRAK4) is involved in the pathophysiology of hidradenitis …

Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …

Background For people with atopic dermatitis (AD) refractory to topical therapies, treatment
with phototherapy and systemic therapies can be considered. Multiple biologic therapies …

Background Phase 3 trials have assessed efficacy of abrocitinib versus placebo in moderate-
to-severe atopic dermatitis, a common immunoinflammatory skin disease. This study …

Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous
presentation and often immense patient burden. Safe, targeted treatment options are …

Over the past two decades, significant progress in understanding of the pathogenesis of type
2 chronic inflammatory diseases has enabled the identification of compounds for more than …